兴齐眼药拟定增募资不超过8.5亿元 进一步加码研发提升创新能力

Core Viewpoint - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. plans to raise up to 850 million yuan through a private placement to enhance R&D innovation and strengthen its market position in the ophthalmic drug sector [1][5] Group 1: Financial Performance - Since its listing in December 2016, the company's revenue has grown from 339 million yuan in 2016 to 1.943 billion yuan in 2024, representing a nearly sixfold increase with a compound annual growth rate (CAGR) of 24.39% [2] - Net profit increased from 54.28 million yuan in 2016 to 338 million yuan in 2024, also showing over sixfold growth and a CAGR of 25.69% [2] - In Q1 of the current year, the company achieved a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, which is more than three times the previous year [2] Group 2: R&D Investment and Strategy - The company maintains a high R&D intensity, with R&D expenditure reaching 235 million yuan in 2024, accounting for 12.11% of its revenue [4] - The planned R&D center aims to create a benchmark in the ophthalmic field, integrating smart laboratory systems, international R&D collaboration, and innovation platforms [4][5] - The implementation of the fundraising project is expected to enhance the company's R&D capabilities, broaden its product pipeline, and optimize existing product structures, ultimately driving sustainable growth [5] Group 3: Competitive Advantage - The company has established a strong competitive advantage in the ophthalmic drug sector due to its focus on R&D and continuous high investment in innovation [3] - The diverse product line covers various common eye diseases, contributing to the company's robust market position [3]